| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8656656 | Atherosclerosis | 2018 | 7 Pages |
Abstract
Our findings suggest that therapeutic silencing of Fsp27 with ASOs may be beneficial in the prevention and management of atherogenic disease in patients with metabolic syndrome.
Keywords
TAGgWATHDLFsp27CIDECASOVLDLHFDPPARhigh-density lipoproteinantisense oligonucleotideAtherosclerosisNon-alcoholic steatohepatitisGonadal white adipose tissuecardiovascular diseaseTriacylglycerideAntisense therapyCVDhigh-fat dietWestern dietMetabolic syndromelipid dropletvery low-density lipoproteinLow-density lipoproteinLDLMETSObesityNash Hypertriglyceridemiafat-specific protein 27peroxisome proliferator-activated receptor
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ananthi Rajamoorthi, Richard G. Lee, Ángel Baldán,